Intellectual Property Law and Copyright Laws

Recent UK case law demonstrates how experimental evidence can decisively influence patent disputes on infringement and validity, but only when parties navigate strict procedural requirements, proportionate disclosure obligations, and careful alignment with patent specifications. Courts increasingly scrutinize the design, statistical rigor, and relevance of experiments while maintaining pragmatic standards for admissibility versus persuasiveness.

The rapid expansion of AI tools for intellectual property work has created an overwhelming landscape for patent attorneys and IP professionals. After analyzing practitioners who have moved beyond evaluation to live implementation, six consistent dimensions have emerged that distinguish truly adoptable AI tools from those that get set aside.

This September edition examines pivotal developments in life sciences patent law across Europe, with the Unified Patent Court continuing to refine its jurisprudence on added matter, intermediary liability, and procedural standards. National courts in the UK, France, and the Netherlands deliver significant rulings on supplementary protection certificates, pro-drugs, and the boundaries of pharmacy exemptions that will shape patent strategy for pharmaceutical and medical device companies.

How is artificial intelligence transforming the creative industries, and what skills will designers need to thrive in an AI-driven future? Industry experts from tangerine, terrible*, The Frank Co., and Cleo explore the evolving relationship between AI, sustainability, and human-centered design in this thought-provoking discussion recorded at the London Design Festival.

An intellectual property lawyer helps businesses protect, register, commercialise and enforce their ideas, brands, products and creative assets. Good advice works in two directions: it helps a business stay on the right side of existing rights and avoid attracting claims, while also shaping its own portfolio so it becomes defensible, valuable and enforceable.

As AI voice cloning technology becomes increasingly sophisticated and accessible, the Save Our Voices Now campaign calls for statutory rights allowing individuals to own and control their voice as intellectual property. This article examines whether existing UK law sufficiently protects one of our most personal and recognisable attributes, exploring copyright, trade marks, passing off, and the practical steps individuals and businesses can take.

M&S and Sephora have launched an exciting brand collaboration that brings together two highly recognisable retail names. Beyond the consumer appeal, this partnership raises important questions about trade mark licensing, co-branding arrangements, and how both parties maintain control over their valuable brand assets throughout the collaboration.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

For many medical technology companies, a patent is the natural starting point when considering intellectual property protection for a new product.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

As computational biology and artificial intelligence reshape drug discovery, pharmaceutical companies face a critical challenge: how to protect not just the final therapeutic compound, but the entire ecosystem of datasets, models, and biological insights that enabled its creation. This article examines the evolving intellectual property landscape where 90% of clinical candidates still fail, yet the tools predicting their success are becoming as valuable as the medicines themselves.

The European Health Data Space (EHDS) regulation has entered into force, creating a harmonised framework for cross-border health data access across the EU. While Europe possesses exceptional health data resources—particularly in Nordic countries with comprehensive patient registries—it has historically lacked the commercial data market infrastructure seen in the United States. This analysis explores how life science companies and investors can position themselves to capitalise on emerging opport